drugset / Trial / NCT01262638

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

NCT01262638

Phase 2 Completed 177 enrolled Esperion Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.

Timeline

Start
2010-12
Primary completion
2011-08-23
Completion
2011-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule 40 mg
Subject Bempedoic acid Small molecule 80 mg
Subject Bempedoic acid Small molecule 120 mg

Indications